Janine Frank, MD
Internal Medicine · Norfolk, VANPI 1164495800
Payments from drug & device makers
Across 63 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$260
- Novo Nordisk$114
- Gilead$104
- Mylan Specialty L.p.$81
- Amarin Pharma, Inc.$72
- Astellas Pharma US Inc$54
- plus $286 from 11 others
What the payments were for
- Food & beverage$972100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $260 |
| Novo Nordisk | 8 | $114 |
| Gilead | 4 | $104 |
| Mylan Specialty L.p. | 7 | $81 |
| Amarin Pharma, Inc. | 4 | $72 |
| Astellas Pharma US Inc | 3 | $54 |
| Lilly USA, LLC | 3 | $39 |
| Amgen | 2 | $32 |
| Merck | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $30 |
| GSK | 2 | $29 |
| Novartis | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| AbbVie | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
How this compares
$972 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $130,713 |
| EliquisApixaban | 113 | $124,345 |
| JanuviaSitagliptin Phosphate | 49 | $68,285 |
| XareltoRivaroxaban | 60 | $65,599 |
| RybelsusSemaglutide | 21 | $36,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $34,631 |
| MounjaroTirzepatide | 30 | $33,340 |
| JardianceEmpagliflozin | 29 | $32,055 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 25 | $27,722 |
| TrulicityDulaglutide | 19 | $26,243 |
| MyrbetriqMirabegron | 26 | $23,990 |
| FarxigaDapagliflozin Propanediol | 15 | $22,109 |
| LinzessLinaclotide | 22 | $20,201 |
| PremarinEstrogens, Conjugated | 20 | $9,858 |
| SynthroidLevothyroxine Sodium | 107 | $7,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $114 | $167,226104 claims |
| MerckJanuvia, Janumet Xr | $30 | $96,00674 claims |
| Lilly USA, LLCMounjaro, Trulicity | $39 | $59,58349 claims |
| GSKTrelegy Ellipta | $29 | $34,63136 claims |
| Boehringer IngelheimJardiance | $27 | $32,05529 claims |
| AbbVieLinzess, Synthroid | $14 | $27,692129 claims |
| AstraZenecaFarxiga, Symbicort | $260 | $26,06328 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $23,99026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Norfolk
- Mary BlumbergNorfolk$6.5M
- Charles LovellNorfolk$1.8M
- Aaron VinikNorfolk$150K
- Edward LillyNorfolk$70K
- Kunal KapoorNorfolk$34K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.